GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Insmed INSM · USD

Health Care · Biotechnology · US listing · 🇺🇸 United States

Compare

116.10

+1.48%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

31 analysts, 1 Nov 2026. The analysts' own views, not ours.

  • 8Strong buy
  • 21Buy
  • 2Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Nov 2026. Not our view.

Average target 197.43

Low
169.00
Average
197.43
Median
197.50
High
235.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$1.84bn$2.95bn$3.92bn$4.97bn$6.22bn
Revenue, highest$1.87bn$3.26bn$4.85bn$5.56bn$6.96bn
Revenue, lowest$1.82bn$2.61bn$3.29bn$4.51bn$5.64bn
Earnings per share-1.570.743.086.4310.13
Earnings per share, highest-1.071.716.497.4211.70
Earnings per share, lowest-2.50-0.060.245.658.90
Analysts101619915

Earnings against forecasts

Earnings per share by fiscal quarter

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Forecast-0.38-0.67-0.98-1.32-1.37-1.32-1.36-1.19
Reported-0.46-0.06-0.76-1.54-1.75-1.70-1.42-1.32
Difference-20.2%+91.1%+22.3%-17.0%-28.1%-28.9%-4.5%-11.2%

Rating changes

Latest broker notes

  • Truist SecuritiesBuy
  • JP MorganOverweight
  • Wells FargoOverweight
  • GuggenheimBuy
  • Evercore ISI GroupOutperform
  • Wells FargoOverweight
  • GuggenheimBuy
  • Evercore ISI GroupOutperform
  • JP MorganOverweight
  • RBC CapitalOutperform
  • Truist SecuritiesBuy
  • Wells FargoOverweight

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

6 / 10

Revenue growth 0.0% a year over 10 years. Return on equity -172.8%.

Model fair value

125.63

From earnings 125.63, from revenue 212.31.

Piotroski score

4 / 9

A nine-point test of financial strength, for 31 Dec 2024.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.